Medicare Expands Coverage of Weight-Loss Drugs for Seniors

According to a report from The Wall Street Journal, as of July 1, 2026, a major Medicare coverage expansion for popular weight-loss drugs has taken effect, putting millions of older Americans on the cusp of more affordable access to these treatments.

Expansion Details

The expansion covers drugs such as Wegovy, Ozempic, and Mounjaro used for weight loss, which were previously covered only for diabetes or specific conditions. Now, Medicare beneficiaries with obesity or overweight plus health risk factors can obtain these drugs at reduced prices.

Context

This decision follows pressure from patient advocacy groups and physicians, as obesity is a significant health issue among seniors. The high cost of these drugs—often over $1,000 per month without insurance—was a major barrier.

Impact on Eli Lilly

Eli Lilly (LLY) is expected to benefit from this expansion, as the company manufactures Mounjaro (tirzepatide), a drug used for weight loss. Increased demand could boost the company's revenue in coming quarters.

What This Means for Investors

This expansion represents a significant growth opportunity for pharmaceutical companies in the obesity space, such as Eli Lilly and Novo Nordisk. However, investors should monitor potential pricing pressures from the government or future competition.